AU2017358402B2 - Reconstituted high density lipoprotein treatment of myocardial infarction - Google Patents

Reconstituted high density lipoprotein treatment of myocardial infarction Download PDF

Info

Publication number
AU2017358402B2
AU2017358402B2 AU2017358402A AU2017358402A AU2017358402B2 AU 2017358402 B2 AU2017358402 B2 AU 2017358402B2 AU 2017358402 A AU2017358402 A AU 2017358402A AU 2017358402 A AU2017358402 A AU 2017358402A AU 2017358402 B2 AU2017358402 B2 AU 2017358402B2
Authority
AU
Australia
Prior art keywords
csl112
renal
placebo
subjects
rhdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017358402A
Other languages
English (en)
Other versions
AU2017358402A1 (en
Inventor
Denise D'ANDREA
Danielle DUFFY
Andreas Gille
Charles Shear
Samuel Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Publication of AU2017358402A1 publication Critical patent/AU2017358402A1/en
Application granted granted Critical
Publication of AU2017358402B2 publication Critical patent/AU2017358402B2/en
Priority to AU2023282314A priority Critical patent/AU2023282314A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017358402A 2016-11-10 2017-11-10 Reconstituted high density lipoprotein treatment of myocardial infarction Active AU2017358402B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023282314A AU2023282314A1 (en) 2016-11-10 2023-12-15 Reconstituted high density lipoprotein treatment of myocardial infarction

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662420050P 2016-11-10 2016-11-10
US62/420,050 2016-11-10
US201762472240P 2017-03-16 2017-03-16
US62/472,240 2017-03-16
PCT/AU2017/051232 WO2018085890A1 (en) 2016-11-10 2017-11-10 Reconstituted high density lipoprotein treatment of myocardial infarction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023282314A Division AU2023282314A1 (en) 2016-11-10 2023-12-15 Reconstituted high density lipoprotein treatment of myocardial infarction

Publications (2)

Publication Number Publication Date
AU2017358402A1 AU2017358402A1 (en) 2019-04-18
AU2017358402B2 true AU2017358402B2 (en) 2023-10-05

Family

ID=62109053

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017358402A Active AU2017358402B2 (en) 2016-11-10 2017-11-10 Reconstituted high density lipoprotein treatment of myocardial infarction
AU2023282314A Pending AU2023282314A1 (en) 2016-11-10 2023-12-15 Reconstituted high density lipoprotein treatment of myocardial infarction

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023282314A Pending AU2023282314A1 (en) 2016-11-10 2023-12-15 Reconstituted high density lipoprotein treatment of myocardial infarction

Country Status (12)

Country Link
US (2) US20200038481A1 (cg-RX-API-DMAC7.html)
EP (1) EP3538105A4 (cg-RX-API-DMAC7.html)
JP (2) JP2019533705A (cg-RX-API-DMAC7.html)
KR (2) KR20190084095A (cg-RX-API-DMAC7.html)
CN (2) CN116196395A (cg-RX-API-DMAC7.html)
AU (2) AU2017358402B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019007709A2 (cg-RX-API-DMAC7.html)
CA (1) CA3043110A1 (cg-RX-API-DMAC7.html)
IL (1) IL266428B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019005459A (cg-RX-API-DMAC7.html)
SG (2) SG11201903945XA (cg-RX-API-DMAC7.html)
WO (1) WO2018085890A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3373828B1 (en) 2015-11-09 2025-12-10 Revamp Medical Ltd. Blood flow reducer for cardiovascular treatment
KR20210102284A (ko) * 2018-12-11 2021-08-19 리벰프 메디컬 리미티드 체강의 혈류를 조절하기 위한 시스템, 장치 및 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269111A1 (en) * 2002-05-17 2008-10-30 Pfizer Inc Method of treating dyslipidemic disorder
WO2015044459A1 (en) * 2013-09-30 2015-04-02 Université Pierre Et Marie Curie - Paris 6 (Upmc) Reconstituted high density lipoproteins composition and uses thereof
AU2013205684B2 (en) * 2012-11-02 2015-08-20 Csl Limited Reconstituted hdl formulation
US20160074473A1 (en) * 2014-07-31 2016-03-17 Kinemed, Inc. Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105396122B (zh) * 2010-06-30 2020-09-11 杰特有限公司 重建高密度脂蛋白制剂及其生产方法
MX377093B (es) 2011-12-21 2025-03-07 Csl Ltd Formulaciones de apolipoproteína de dosificación fija.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269111A1 (en) * 2002-05-17 2008-10-30 Pfizer Inc Method of treating dyslipidemic disorder
AU2013205684B2 (en) * 2012-11-02 2015-08-20 Csl Limited Reconstituted hdl formulation
WO2015044459A1 (en) * 2013-09-30 2015-04-02 Université Pierre Et Marie Curie - Paris 6 (Upmc) Reconstituted high density lipoproteins composition and uses thereof
US20160074473A1 (en) * 2014-07-31 2016-03-17 Kinemed, Inc. Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIDICHENKO, S ET AL.: "NOVEL FORMULATION OF A HIGH- DENSITY LIPOPROTEIN (CSL112) DRAMATICALLY ENHANCES ABCA1- DEPENDENT CHOLESTEROL EFFLUX", ARTERIOSCLEROTIC THROMB VASC BIOL., vol. 33, 2013, pages 2202 - 2211, XP055483786 *
TRICOCI, P ET AL.: , JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 4, no. 8, 2015, pages e002171, XP055352843 *

Also Published As

Publication number Publication date
IL266428B1 (en) 2024-08-01
BR112019007709A2 (pt) 2019-07-09
SG10201911714YA (en) 2020-02-27
CN109922810A (zh) 2019-06-21
AU2017358402A1 (en) 2019-04-18
WO2018085890A1 (en) 2018-05-17
JP2022116254A (ja) 2022-08-09
KR20190084095A (ko) 2019-07-15
IL266428B2 (en) 2024-12-01
MX2019005459A (es) 2019-08-12
CA3043110A1 (en) 2018-05-17
AU2023282314A1 (en) 2024-01-18
SG11201903945XA (en) 2019-05-30
JP7464654B2 (ja) 2024-04-09
JP2019533705A (ja) 2019-11-21
US20240207357A1 (en) 2024-06-27
RU2019117552A3 (cg-RX-API-DMAC7.html) 2021-06-25
EP3538105A4 (en) 2020-05-20
IL266428A (en) 2019-06-30
KR20240044543A (ko) 2024-04-04
CN116196395A (zh) 2023-06-02
EP3538105A1 (en) 2019-09-18
RU2019117552A (ru) 2020-12-10
US20200038481A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
Feingold Triglyceride lowering drugs
Hovingh et al. The effect of an apolipoprotein AI–containing high-density lipoprotein–mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study
Palladini et al. Novel strategies for the diagnosis and treatment of cardiac amyloidosis
AU2023282314A1 (en) Reconstituted high density lipoprotein treatment of myocardial infarction
JP2025038063A (ja) 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
US11957731B2 (en) Reconstituted HDL formulation
Boini et al. Instigation of NLRP3 inflammasome activation and glomerular injury in mice on the high fat diet: role of acid sphingomyelinase gene
Gibson et al. Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): a phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction
Baldassarre et al. Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment
Schonck et al. Long-term efficacy and tolerability of PCSK9 targeted therapy: a review of the literature
Kones et al. Current treatment of dyslipidemia: evolving roles of non-statin and newer drugs
Ortega-Paz et al. Clinical pharmacokinetics and pharmacodynamics of CSL112
CN109789217A (zh) 用于降低脂蛋白颗粒对动脉壁酶引起的致动脉粥样硬化性聚集的敏感度的方法和试剂盒
RU2798830C2 (ru) Лечение восстановленным липопротеином высокой плотности инфаркта миокарда
Gagel et al. What is the optimal low-density lipoprotein cholesterol?
Candido et al. Linking diabetes and atherosclerosis
WO2025210584A1 (en) Reconstituted high density lipoprotein treatment of myocardial infarction
Skoczyńska et al. Postprandial lipemia in diabetic men during hypolipemic therapy
Robinson et al. Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport
Louis Lipid-lowering drug therapies and chronic obstructive pulmonary disease: lung failure or just heart failure?
Gouni-Berthold et al. Mipomersen: a lipid-lowering agent with a novel mechanism of action
Sirtori et al. High density lipoprotein administration: a new therapeutic modality for the treatment of cardiovascular diseases
White Darapladib and its potential for plaque stabilization and prevention of cardiac events
Thompson et al. 44 Lipid management after a coronary
Errico et al. Macrophage-to-feces reverse cholesterol transport is impaired in a mouse model of diabetes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)